Who are Havrix®720's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Havrix Junior, Engerix-B and Twinrix, Havrix+Healive, Havrix (HAV), Comparator: VAQTA™, Healive+Healive.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/havrix720.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Havrix®720 — Competitive Intelligence Brief

Havrix®720 (Havrix®720) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Inactivated viral vaccine. Area: Immunology / Infectious Disease.

phase 3 Inactivated viral vaccine Hepatitis A virus antigen Immunology / Infectious Disease Biologic Live · refreshed every 30 min

Target snapshot

Havrix®720 (Havrix®720) — Valneva Austria GmbH. Havrix 720 is an inactivated hepatitis A vaccine that stimulates the immune system to produce antibodies against hepatitis A virus.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Havrix®720 TARGET	Havrix®720	Valneva Austria GmbH	phase 3	Inactivated viral vaccine	Hepatitis A virus antigen
Havrix Junior	Havrix Junior	GlaxoSmithKline	marketed	Inactivated viral vaccine	Hepatitis A virus antigen
Engerix-B and Twinrix	Engerix-B and Twinrix	St. Joseph's Health Care London	marketed	Vaccine	Hepatitis B surface antigen (HBsAg); Hepatitis A virus antigen
Havrix+Healive	Havrix+Healive	Sinovac Biotech Co., Ltd	marketed	Combination inactivated viral vaccine	Hepatitis A virus antigen; Hepatitis B surface antigen (HBsAg)
Havrix (HAV)	Havrix (HAV)	Pfizer	marketed	Inactivated viral vaccine	Hepatitis A virus antigen
Comparator: VAQTA™	Comparator: VAQTA™	Merck Sharp & Dohme LLC	marketed	Inactivated viral vaccine	Hepatitis A virus antigen
Healive+Healive	Healive+Healive	Sinovac Biotech Co., Ltd	marketed	Combination vaccine	Hepatitis A virus antigen; Hepatitis B surface antigen (HBsAg)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Inactivated viral vaccine class)

Sinovac Biotech Co., Ltd · 9 drugs in this class
Sanofi Pasteur, a Sanofi Company · 9 drugs in this class
GlaxoSmithKline · 5 drugs in this class
Valneva Austria GmbH · 4 drugs in this class
Medical University of Vienna · 3 drugs in this class
Centers for Disease Control and Prevention · 3 drugs in this class
China National Biotec Group Company Limited · 2 drugs in this class
Statens Serum Institut · 2 drugs in this class
Institute of Medical Biology, Chinese Academy of Medical Sciences · 2 drugs in this class
Crucell Holland BV · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Havrix®720 — Competitive Intelligence Brief. https://druglandscape.com/ci/havrix720. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab